Sotirija Duvlis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sotirija Duvlis has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Dijana Plaseska-Karanfilska
Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Science and Arts, Skopje, North Macedonia
1 shared publication Katerina Popovska-Jankovic
Research Center for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Science and Arts, Skopje, Republic of Macedonia
1 shared publicationShaban Memeti
Institute of Public Health of R. Macedonia, Skopje, Republic of Macedonia
1 shared publicationZaneta Popeska
Faculty of Computer Science and Engineering, Ss. Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia
1 shared publicationZorica Sarafinovska Arsova
Institute of Public Health of R. Macedonia, Skopje, Republic of Macedonia
1 shared publication
Latest Publications
- 16 April 2015
- Published by Wiley in Journal of Medical Virology
- Vol. 87 (9) , 1578-1586
HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women
High risk types of human papillomaviruses E6/E7 oncogenes and their association with tumor suppressor genes products are the key factors of cervical carcinogenesis. This study proposed them as specific markers for cervical dysplasia screening. The aim of the study is to compare the clinical and prognostic significance of HPV E6/E7 mRNA as an early biomarker versus HPV DNA detection and cytology in triage of woman for cervical cancer. The study group consists of 413 women: 258 NILM, 26 ASC‐US, 81 LSIL, 41 HSIL, and 7 unsatisfactory cytology. HPV4AACE screening, real‐time multiplex PCR and MY09/11 consensus PCR primers methods were used for the HPV DNA detection. The real‐time multiplex nucleic acid sequence‐based assay (NucliSENS EasyQ HPV assay) was used for HPV E6/E7 mRNA detection of the five most common high risk HPV types in cervical cancer (16, 18, 31, 33, and 45). The results show that HPV E6/E7 mRNA testing had a higher specificity 50% (95% CI 32–67) and positive predictive value (PPV) 62% (95% CI 46–76) for CIN2+ compared to HPV DNA testing that had specificity of 18% (95% CI 7–37) and PPV 52% (95% CI 39–76) respectively. The higher specificity and PPV of HPV E6/E7 mRNA testing are valuable in predicting insignificant HPV DNA infection among cases with borderline cytological finding. It can help in avoiding aggressive procedures (biopsies and over‐referral of transient HPV infections) as well as lowering patient's anxiety and follow up period. J. Med. Virol. 87:1578–1586, 2015.
- 16 April 2015
- Published by Wiley in Journal of Medical Virology
- Vol. 87 (9) , 1578-1586
HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women
High risk types of human papillomaviruses E6/E7 oncogenes and their association with tumor suppressor genes products are the key factors of cervical carcinogenesis. This study proposed them as specific markers for cervical dysplasia screening. The aim of the study is to compare the clinical and prognostic significance of HPV E6/E7 mRNA as an early biomarker versus HPV DNA detection and cytology in triage of woman for cervical cancer. The study group consists of 413 women: 258 NILM, 26 ASC‐US, 81 LSIL, 41 HSIL, and 7 unsatisfactory cytology. HPV4AACE screening, real‐time multiplex PCR and MY09/11 consensus PCR primers methods were used for the HPV DNA detection. The real‐time multiplex nucleic acid sequence‐based assay (NucliSENS EasyQ HPV assay) was used for HPV E6/E7 mRNA detection of the five most common high risk HPV types in cervical cancer (16, 18, 31, 33, and 45). The results show that HPV E6/E7 mRNA testing had a higher specificity 50% (95% CI 32–67) and positive predictive value (PPV) 62% (95% CI 46–76) for CIN2+ compared to HPV DNA testing that had specificity of 18% (95% CI 7–37) and PPV 52% (95% CI 39–76) respectively. The higher specificity and PPV of HPV E6/E7 mRNA testing are valuable in predicting insignificant HPV DNA infection among cases with borderline cytological finding. It can help in avoiding aggressive procedures (biopsies and over‐referral of transient HPV infections) as well as lowering patient's anxiety and follow up period. J. Med. Virol. 87:1578–1586, 2015.